Telephone-based cognitive behavioral therapy seems to be an effective intervention for depression in Parkinson disease, outperforming treatment-as-usual on all depression, anxiety, and quality-of-life measures.
Patients with Parkinson disease tend to have an increase in iron content with reduced perfusion in the substantia nigra.
Can mere light become a revolutionary new treatment for traumatic brain injury, posttraumatic stress disorder, depression, stroke, Parkinson disease, and Alzheimer disease?
Up to half of patients with Parkinson disease are also diagnosed with dementia, but tools to track changes in cognition are lacking.
Patients with Parkinson disease have a higher prevalence of ophthalmologic symptoms than controls.
Stress-related disorders are associated with an increased risk for neurodegenerative diseases.
There is a distinct genetic signature for young-onset Parkinson disease even in cells from those who have no known Parkinson disease-related mutations.
A physically active lifestyle is associated with a reduced risk for Parkinson disease.
Olfactory dysfunction is a marker for a number of neuropsychiatric disorders, including Parkinson disease, Alzheimer disease, and schizophrenia.
In long-term care facilities, the rate of antipsychotic use in patients with PD ranges from 15% to 30%; however, the efficacy of AAPs in these patients has not been evaluated in large clinical trials.
